This pharmaceutical company has another new ADC drug for clinical application!

ADC is a new class of targeted drugs composed of monoclonal antibodies, cytotoxic drugs and linkers that connect the two.
It utilizes the targeting of antibodies to selectively deliver cytotoxic molecules to tumor cells, and play a role in anti-inflammatory drugs.
It does not affect healthy cells while preventing cancer
.
According to data, the current global ADC drug market scale has reached 10 billion US dollars, and there are more than 600 new ADC drug projects under research
.
Due to the broad prospects of the ADC drug market and the huge unmet market demand, it is also attracting more and more local pharmaceutical companies to accelerate their deployment in this track
.
Recently, Bio-Tech's class 1 new drug BAT8010 has been submitted for clinical application
.
The target and category of the drug have not yet been disclosed, but according to Bio-Tech's previous product naming rules, BAT8010 is likely to be a new ADC drug
.
It is worth noting that Bio-Thera has actually had two new ADC drugs approved for clinical trials this year, and BAT8010 is the third ADC to apply for clinical trials
.
It is reported that ADC is one of the bright spots in Bio-Tech’s pipeline, but at the beginning of 2021, Bio-Tech terminated 3 new drug projects in succession, including 2 ADCs and 1 PD-1 monoclonal antibody, with a related investment of 340 million yuan.
Drift
.
At that time, there were also rumors that Bio-Tech would completely withdraw from the development of ADC in the future
.
However, from the current point of view, Bio-Tech has started anew in the ADC field
.
BAT8006 and BAT8009 target FRα and B7H3, respectively, which are relatively inaccessible new targets in China with promising potential
.
Specifically, BAT8009, which was also approved for clinical use in April, is a B7H3-targeting antibody-drug conjugate (ADC) developed by Bio-Tech, which is intended to be developed for the treatment of solid tumors
.
B7H3 (also known as CD276) is a membrane protein member of the immunomodulatory protein B7 family.
It is highly expressed in a variety of solid tumors, plays a role in tumor development, immune escape and other processes, and is associated with poor tumor prognosis.

.
BAT8009 has shown high antitumor activity in both in vitro and in vivo pharmacological studies, and is a potential "best-in-class" antibody conjugated drug targeting B7H3
.
BAT8006, which was approved for clinical use before this, is the first ADC developed by Bio-Tech using its self-developed new ADC platform to enter the clinic.
ADC (ADC), intended to be developed for the treatment of solid tumors
.
In terms of efficacy, BAT8006 has efficient anti-tumor activity, and the small toxin molecule has strong cell membrane penetration ability, as well as good stability and safety.
It is a potential "best-in- class" antibody-drug conjugates
.
In addition to Bio-Tech, in fact, in the past two years, it can be seen that multinational pharmaceutical companies such as Gilead, Merck, Boehringer Ingelheim, etc.
have been intensively completing the layout of ADC assets; and many domestic leading pharmaceutical companies are also using License in or investment.
The form of equity participation in order to quickly cut into this huge potential drug field
.
In this regard, the industry generally believes that the fierce competition in this field will be imagined in the future
.
But in general, efficient clinical advancement and differentiated indication development strategies in the future will still be the key to ADC drug layout pharmaceutical companies to gain market competitive advantage
.
And this will obviously be beneficial to ADC R&D manufacturers with strong self-research capabilities and differentiated pipeline target layouts, such as Bio-Tech
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.